Humoral response to SARS-CoV-2 is well preserved and symptom dependent in kidney transplant recipients
Language English Country United States Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
Grant support
NV19-06-00031
Ministerstvo Zdravotnictví Ceské Republiky
PubMed
34212497
PubMed Central
PMC9906442
DOI
10.1111/ajt.16746
PII: S1600-6135(22)08840-2
Knihovny.cz E-resources
- Keywords
- clinical research/practice, infection and infectious agents - viral, infectious disease, kidney transplantation/nephrology, patient characteristics,
- MeSH
- COVID-19 * MeSH
- Humans MeSH
- Pandemics MeSH
- Transplant Recipients MeSH
- Antibodies, Viral MeSH
- SARS-CoV-2 MeSH
- Seroepidemiologic Studies MeSH
- Kidney Transplantation * adverse effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antibodies, Viral MeSH
Data on the immune response to SARS-CoV-2 in kidney transplant recipients are scarce. Thus, we conducted a single-center observational study to assess the anti-SARS-CoV-2 IgG seroprevalence in outpatient kidney transplant recipients (KTR; n = 1037) and healthcare workers (HCW; n = 512) during the second wave of the COVID-19 pandemic in fall 2020 and evaluated the clinical variables affecting antibody levels. Antibodies against S1 and S2 subunit of SARS-CoV-2 were evaluated using immunochemiluminescent assay (cut off 9.5 AU/ml, sensitivity of 91.2% and specificity of 90.2%). Anti-SARS-CoV-2 IgG seroprevalence was lower in KTR than in HCW (7% vs. 11.9%, p = .001). Kidney transplant recipients with SARS-CoV-2 infection were younger (p = .001) and received CNI-based immunosuppression more frequently (p = .029) than seronegative KTR. Anti-SARS-CoV-2 IgG positive symptomatic KTR had a higher BMI (p = .04) than asymptomatic KTR. Interestingly, anti-SARS-CoV-2 IgG levels were higher in KTR than in HCW (median 31 AU/ml, IQR 17-84 vs. median 15 AU/ml, IQR 11-39, p < .001). The presence of moderate to severe symptoms in KTR was found to be the only independent factor affecting IgG levels (Beta coefficient = 41.99, 95% CI 9.92-74.06, p = .011) in the multivariable model. In conclusion, KTR exhibit a well-preserved symptom-dependent humoral response to SARS-CoV-2 infection.
Department of Immunology Institute for Clinical and Experimental Medicine Prague Czech Republic
Department of Informatics Institute for Clinical and Experimental Medicine Prague Czech Republic
See more in PubMed
Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in down syndrome: results from a cohort study of 8 million adults [published online ahead of print October 21, 2020] Ann Intern Med. 2021;174(4):572–576. PubMed PMC
Phanish M, Ster IC, Ghazanfar A, et al. Systematic review and meta-analysis of COVID-19 and kidney transplant recipients, the South West London Kidney Transplant Network experience [published online ahead of print December 19, 2020] Kidney Int Rep. 2021;6(3):574–585. PubMed PMC
Choi M, Bachmann F, Naik MG, et al. Low seroprevalence of SARS-CoV-2 antibodies during systematic antibody screening and serum responses in patients after COVID-19 in a German Transplant Center. J Clin Med. 2020;9(11):3401. Published October 23, 2020. PubMed PMC
Prendecki M, Clarke C, Gleeson S, et al. Detection of SARS-CoV-2 antibodies in kidney transplant recipients. J Am Soc Nephrol. 2020;31(12):2753–2756. PubMed PMC
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein [published correction appears in Cell. 2020;183(6):1735] Cell. 2020;181(2):281–292. e6. PubMed PMC
Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11:610688. Published December 18, 2020. PubMed PMC
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. Accessed 25 Mar 2021. PubMed
Bonelli F, Sarasini A, Zierold C, et al. Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol. 2020;58(9):e01224–e01320. Published August 24, 2020. PubMed PMC
National SARS-CoV-2 Serology Assay Evaluation Group Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison [published correction appears in Lancet Infect Dis. 2020 Dec;20(12):e298] Lancet Infect Dis. 2020;20(12):1390–1400. PubMed PMC
Burack D, Pereira MR, Tsapepas DS, et al. Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection [published online ahead of print February 16, 2021] Am J Transplant. 2021;21(6):2254–2261. PubMed PMC
Sakhi H, Dahmane D, Attias P, et al. Kinetics of anti-SARS-CoV-2 IgG antibodies in hemodialysis patients six months after infection [published online ahead of print February 26, 2021] J Am Soc Nephrol. 2021;32(5):1033–1036. PubMed PMC
Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients [published online ahead of print May 5, 2021] JAMA. 2021;325(21):2204–2206. PubMed PMC
Marion O, Del Bello A, Abravanel F, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants [published online ahead of print May 25, 2021]. Ann Intern Med. 2021. 10.7326/M21-1341. PubMed DOI PMC
Aslam S, Danziger-Isakov L, Mehra MR. COVID-19 vaccination immune paresis in heart and lung transplantation [published online ahead of print May 13, 2021]. J Heart Lung Transplant. 2021. 10.1016/j.healun.2021.04.018. PubMed DOI PMC
Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120–134. PubMed PMC
Pallett SJC, Rayment M, Patel A, et al. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study [published correction appears in Lancet Respir Med. July 30, 2020] Lancet Respir Med. 2020;8(9):885–894. PubMed PMC
Huang YI, Lu Y, Huang Y-M, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113:154378. PubMed PMC
Ko JH, Joo EJ, Park SJ, et al. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients. J Clin Med. 2020;9(7):2268. Published July 17, 2020. PubMed PMC
Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147(2):545–557. e9. PubMed PMC
Zhou W, Xu X, Chang Z, et al. The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19. J Med Virol. 2021;93(2):924–933. PubMed PMC
Chavarot N, Leruez-Ville M, Scemla A, et al. Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. Kidney Int. 2021;99(2):486–488. PubMed PMC
COVID-19 map – Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed May 18, 2021.